Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  De Cecco, Loris ^a   Berardi, Martina ^a   Sommariva, Michele ^a,b   Cataldo, Alessandra ^b   Canevari, Silvana ^a   Mezzanzanica, Delia ^a   Iorio, Marilena V ^a   Tagliabue, Elda ^a   Balsari, Andrea ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; HISTONE DEACETYLASE 4; MESSENGER RNA; MICRORNA; MICRORNA 302B; MICRORNA 340; MICRORNA 424; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENE SEQUENCE; HDAC4 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; PROTEIN EXPRESSION; RNA ANALYSIS; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; CISPLATIN; COMPUTATIONAL BIOLOGY; DRUG THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LUCIFERASES; MICE; MICRORNAS; OLIGODEOXYRIBONUCLEOTIDES; OVARIAN NEOPLASMS; PLASMIDS; PLATINUM; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84874618655     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058849     Document Type: Article

References (39)

1. Krieg AM, (2007) Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4: 289-94.
2. Abreu MT, Fukata M, Arditi M, (2005) TLR signaling in the gut in health and disease. J Immunol 174: 4453-60.
3. Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, et al. (2011) TLR9-agonists oppositely modulate DNA-repair genes in tumor vesus immune cells and ehance chemotherapy effects. Cancer Res 71: 6382-90.
4. De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, et al. (2008) Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 14: 5512-8.
5. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-14.
6. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-33.
7. Griffiths-Jones S, Saini HK, van DS, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-D158.
8. Griffiths-Jones S, Grocock RJ, van DS, Bateman A, Enright AJ, (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144.
9. Griffiths-Jones S, (2004) The microRNA Registry. Nucleic Acids Res 32: D109-D111.
10. Hermeking H, (2012) MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12: 613-26.
11. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
12. Wu S, Huang S, Ding J, Zhao Y, Liang L, et al. (2010) Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene 29: 2302-8.
13. Allen KE, Weiss GJ, (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9: 3126-36.
14. Landau DA, Slack FJ, (2011) MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol 38: 743-51.
15. Hu H, Gatti RA, (2011) MicroRNAs: new players in the DNA damage response. J Mol Cell Biol 3: 151-8.
16. Sommariva M, De Cecco L, Tagliabue E, Balsari A, (2012) Modulation of DNA repair genes induced by TLR9 agonists. A strategy to elimate "altered" cells? OncoImmunology 1: 258-9.
17. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, et al. (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45: 4970-9.
18. Wright GW, Simon RM, (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-55.
19. Sales G, Coppe A, Bisognin A, Biasiolo M, Bortoluzzi S, et al. (2010) MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res 38: W352-W359.
20. Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, et al. (2011) A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 121: 444-50.
21. Bagnoli M, De CL, Granata A, Nicoletti R, Marchesi E, et al. (2011) Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2: 1265-78.
22. Johnson WE, Li C, Rabinovic A, (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-27.
23. Dolezalova D, Mraz M, Barta T, Plevova K, Vinarsky V, et al. (2012) MicroRNAs regulate p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells. Stem Cells 30: 1362-72.
24. Berezikov E, Thuemmler F, van Laake LW, Kondova I, Bontrop R, et al. (2006) Diversity of microRNAs in human and chimpanzee brain. Nat Genet 38: 1375-7.
25. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-5.
26. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, et al. (2010) Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57: 734-43.
27. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, et al. (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 71: 4412-22.
28. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD, (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9: 839-45.
29. Lodish HF, Zhou B, Liu G, Chen CZ, (2008) Micromanagement of the immune system by microRNAs. Nat Rev Immunol 8: 120-30.
30. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D, (2010) Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10: 111-22.
31. Nahid MA, Satoh M, Chan EK, (2011) MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol 8: 388-403.
32. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-9.
33. Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, et al. (2010) The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol 21: 262-8.
34. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, et al. (2008) Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99: 376-84.
35. Stiborova M, Eckschlager T, Poljakova J, Hrabeta J, Adam V, et al. (2012) The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem.
36. Thurn KT, Thomas S, Moore A, Munster PN, (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7: 263-83.
37. Gryder BE, Sodji QH, Oyelere AK, (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4: 505-24.
38. Miska EA, (2005) How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15: 563-8.
39. Jackson AL, Levin AA, (2012) Developing microRNA Therapeutics: Approaching the Unique Complexities. Nucleic Acid Ther 22: 213-25.